Cancer Epidemiology Biomarkers & Prevention, Vol 7, Issue 2 97-102, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer

DC Farrow, TL Vaughan, PD Hansten, JL Stanford, HA Risch, MD Gammon, WH Chow, R Dubrow, H Ahsan, ST Mayne, JB Schoenberg, AB West, H Rotterdam, JF Fraumeni Jr and WJ Blot
Fred Hutchinson Cancer Research Center, Program in Epidemiology, Seattle, Washington 98109-1024, USA.

Regular users of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are at reduced risk of colon cancer, but the evidence for protective effects of NSAIDs elsewhere in the digestive tract is scant. We investigated the association between the use of NSAIDs and risk of esophageal and gastric cancer, using data from a large population-based, case-control study. Cases were individuals, ages 30-79 years, diagnosed with esophageal adenocarcinoma (n = 293), esophageal squamous cell carcinoma (n = 221), gastric cardia adenocarcinoma (n = 261), or noncardia gastric adenocarcinoma (n = 368) in three areas with population-based tumor registries. Controls (n = 695) were selected by random digit dialing and through the rosters of the Health Care Financing Administration. After controlling for the major risk factors, we found that current users of aspirin were at decreased risk of esophageal adenocarcinoma [odds ratio (OR), 0.37; 95% confidence interval (CI), 0.24-0.58], esophageal squamous cell carcinoma (OR, 0.49; 95% CI, 0.28-0.87), and noncardia gastric adenocarcinoma (OR, 0.46; 95% CI, 0.31-0.68), but not of gastric cardia adenocarcinoma (OR, 0.80; 95% CI, 0.54-1.19), when compared to never users. Risk was similarly reduced among current users of nonaspirin NSAIDs. The associations with current NSAID use persisted when we excluded use within 2 or 5 years of reference date, which might have been affected by preclinical disease in cases, and when we restricted analyses to subjects reporting no history of chronic gastrointestinal symptoms. Our findings add to the growing evidence that the risk of cancers of the esophagus and stomach is reduced in users of NSAIDs, although whether the association is causal in nature is not clear.

This article has been cited by other articles:

				J. A. Abrams Review: Chemoprevention of esophageal adenocarcinoma Therapeutic Advances in Gastroenterology, July 1, 2008; 1(1): 7 - 18. [Abstract] [PDF]

				S. Sadeghi, C. J. Bain, N. Pandeya, P. M. Webb, A. C. Green, D. C. Whiteman, and for the Australian Cancer Study Aspirin, Nonsteroidal Anti-inflammatory Drugs, and the Risks of Cancers of the Esophagus Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1169 - 1178. [Abstract] [Full Text] [PDF]

				L. Duan, A. H. Wu, J. Sullivan-Halley, and L. Bernstein Nonsteroidal Anti-inflammatory Drugs and Risk of Esophageal and Gastric Adenocarcinomas in Los Angeles County Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 126 - 134. [Abstract] [Full Text] [PDF]

				R. A. Risques, T. L. Vaughan, X. Li, R. D. Odze, P. L. Blount, K. Ayub, J. L. Gallaher, B. J. Reid, and P. S. Rabinovitch Leukocyte Telomere Length Predicts Cancer Risk in Barrett's Esophagus Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2649 - 2655. [Abstract] [Full Text] [PDF]

				H. Makita, M. Mutoh, T. Maruyama, K. Yonemoto, A. Kobayashi, H. Fujitsuka, M. Toida, T. Shibata, S. Miyamoto, Y. Yasui, et al. A prostaglandin E2 receptor subtype EP1-selective antagonist, ONO-8711, suppresses 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis Carcinogenesis, March 1, 2007; 28(3): 677 - 684. [Abstract] [Full Text] [PDF]

				R C Fitzgerald Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. Gut, December 1, 2006; 55(12): 1810 - 1820. [Full Text] [PDF]

				J. H. Hayes, K. E. Anderson, and A. R. Folsom Association between Nonsteroidal Anti-inflammatory Drug Use and the Incidence of Lung Cancer in the Iowa Women's Health Study. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2226 - 2231. [Abstract] [Full Text] [PDF]

				E. D. Flick, K. A. Chan, P. M. Bracci, and E. A. Holly Use of Nonsteroidal Antiinflammatory Drugs and Non-Hodgkin Lymphoma: A Population-based Case-Control Study Am. J. Epidemiol., September 1, 2006; 164(5): 497 - 504. [Abstract] [Full Text] [PDF]

				N. Joshi, L. L. Johnson, W.-Q. Wei, C. C. Abnet, Z.-W. Dong, P. R. Taylor, P. J. Limburg, S. M. Dawsey, E. T. Hawk, Y.-L. Qiao, et al. Gene Expression Differences in Normal Esophageal Mucosa Associated with Regression and Progression of Mild and Moderate Squamous Dysplasia in a High-Risk Chinese Population. Cancer Res., July 1, 2006; 66(13): 6851 - 6860. [Abstract] [Full Text] [PDF]

				K Fall, W Ye, and O Nyren Antibiotic treatment and risk of gastric cancer Gut, June 1, 2006; 55(6): 793 - 796. [Abstract] [Full Text] [PDF]

				L. A. Anderson, B. T. Johnston, R.G. P. Watson, S. J. Murphy, H. R. Ferguson, H. Comber, J. McGuigan, J. V. Reynolds, and L. J. Murray Nonsteroidal Anti-inflammatory Drugs and the Esophageal Inflammation-Metaplasia-Adenocarcinoma Sequence. Cancer Res., May 1, 2006; 66(9): 4975 - 4982. [Abstract] [Full Text] [PDF]

				H. Lu, W. Ouyang, and C. Huang Inflammation, a Key Event in Cancer Development Mol. Cancer Res., April 1, 2006; 4(4): 221 - 233. [Abstract] [Full Text] [PDF]

				P. Lao-Sirieix, A. Roy, C. Worrall, S. L. Vowler, S. Gardiner, and R. C. Fitzgerald Effect of Acid suppression on molecular predictors for esophageal cancer. Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 288 - 293. [Abstract] [Full Text] [PDF]

				S. R. DeMeester Adenocarcinoma of the Esophagus and Cardia: A Review of the Disease and Its Treatment Ann. Surg. Oncol., January 1, 2006; 13(1): 12 - 30. [Abstract] [Full Text] [PDF]

				K. B. Moysich, J. A. Baker, K. J. Rodabaugh, and J. A. Villella Regular Analgesic Use and Risk of Endometrial Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2005; 14(12): 2923 - 2928. [Abstract] [Full Text] [PDF]

				K. J. Smith, S. M. O'Brien, B. M. Smithers, D. C. Gotley, P. M. Webb, A. C. Green, D. C. Whiteman, and for the Study of Digestive Health Interactions among Smoking, Obesity, and Symptoms of Acid Reflux in Barrett's Esophagus Cancer Epidemiol. Biomarkers Prev., November 1, 2005; 14(11): 2481 - 2486. [Abstract] [Full Text] [PDF]

				R. F. Souza and S. J. Spechler Concepts in the Prevention of Adenocarcinoma of the Distal Esophagus and Proximal Stomach CA Cancer J Clin, November 1, 2005; 55(6): 334 - 351. [Abstract] [Full Text] [PDF]

				A. R. Kristal, P. L. Blount, J. M. Schenk, C. A. Sanchez, P. S. Rabinovitch, R. D. Odze, J. Standley, T. L. Vaughan, and B. J. Reid Low-Fat, High Fruit and Vegetable Diets and Weight Loss Do Not Affect Biomarkers of Cellular Proliferation in Barrett Esophagus Cancer Epidemiol. Biomarkers Prev., October 1, 2005; 14(10): 2377 - 2383. [Abstract] [Full Text] [PDF]

				S. I. Abdalla, I. R. Sanderson, and R. C. Fitzgerald Effect of inflammation on cyclooxygenase (COX)-2 expression in benign and malignant oesophageal cells Carcinogenesis, September 1, 2005; 26(9): 1627 - 1633. [Abstract] [Full Text] [PDF]

				G. D. Stoner, H. Qin, T. Chen, P. S. Carlton, M. E. Rose, R. M. Aziz, and R. Dixit The effects of L-748706, a selective cyclooxygenase-2 inhibitor, on N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis Carcinogenesis, September 1, 2005; 26(9): 1590 - 1595. [Abstract] [Full Text] [PDF]

				C. C Abnet, Y.-L. Qiao, S. M Dawsey, Z.-W. Dong, P. R Taylor, and S. D Mark Tooth loss is associated with increased risk of total death and death from upper gastrointestinal cancer, heart disease, and stroke in a Chinese population-based cohort Int. J. Epidemiol., April 1, 2005; 34(2): 467 - 474. [Abstract] [Full Text] [PDF]

				J. R. Olliver, L. J. Hardie, Y. Gong, S. Dexter, D. Chalmers, K. M. Harris, and C. P. Wild Risk Factors, DNA Damage, and Disease Progression in Barrett's Esophagus Cancer Epidemiol. Biomarkers Prev., March 1, 2005; 14(3): 620 - 625. [Abstract] [Full Text] [PDF]

				S. Mima, S. Tsutsumi, H. Ushijima, M. Takeda, I. Fukuda, K. Yokomizo, K. Suzuki, K. Sano, T. Nakanishi, W. Tomisato, et al. Induction of Claudin-4 by Nonsteroidal Anti-inflammatory Drugs and Its Contribution to Their Chemopreventive Effect Cancer Res., March 1, 2005; 65(5): 1868 - 1876. [Abstract] [Full Text] [PDF]

				J Lagergren Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut, March 1, 2005; 54(suppl_1): i1 - i5. [Abstract] [Full Text] [PDF]

				R C Fitzgerald Barrett's oesophagus and oesophageal adenocarcinoma: how does acid interfere with cell proliferation and differentiation? Gut, March 1, 2005; 54(suppl_1): i21 - i26. [Abstract] [Full Text] [PDF]

				M. Lindblad, J. Lagergren, and L. A. Garcia Rodriguez Nonsteroidal Anti-inflammatory Drugs and Risk of Esophageal and Gastric Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 444 - 450. [Abstract] [Full Text] [PDF]

				M. Ishikawa, J. Kitayama, S. Kazama, T. Hiramatsu, K. Hatano, and H. Nagawa Plasma Adiponectin and Gastric Cancer Clin. Cancer Res., January 15, 2005; 11(2): 466 - 472. [Abstract] [Full Text] [PDF]

				V. Y. Shin, W. K.K. Wu, Y.-N. Ye, W. H.L. So, M. W.L. Koo, E. S.L. Liu, J.-C. Luo, and C.-H. Cho Nicotine promotes gastric tumor growth and neovascularization by activating extracellular signal-regulated kinase and cyclooxygenase-2 Carcinogenesis, December 1, 2004; 25(12): 2487 - 2495. [Abstract] [Full Text] [PDF]

				N. R. Sivak-Sears, J. A. Schwartzbaum, R. Miike, M. Moghadassi, and M. Wrensch Case-Control Study of Use of Nonsteroidal Antiinflammatory Drugs and Glioblastoma Multiforme Am. J. Epidemiol., June 15, 2004; 159(12): 1131 - 1139. [Abstract] [Full Text] [PDF]

				M. B. Terry, M. D. Gammon, F. F. Zhang, H. Tawfik, S. L. Teitelbaum, J. A. Britton, K. Subbaramaiah, A. J. Dannenberg, and A. I. Neugut Association of Frequency and Duration of Aspirin Use and Hormone Receptor Status With Breast Cancer Risk JAMA, May 26, 2004; 291(20): 2433 - 2440. [Abstract] [Full Text] [PDF]

				C. M. Ulrich, J. Bigler, R. Sparks, J. Whitton, J. G. Sibert, E. L. Goode, Y. Yasui, and J. D. Potter Polymorphisms in PTGS1 (=COX-1) and Risk of Colorectal Polyps Cancer Epidemiol. Biomarkers Prev., May 1, 2004; 13(5): 889 - 893. [Abstract] [Full Text] [PDF]

				J Dent, D Armstrong, B Delaney, P Moayyedi, N J Talley, and N Vakil Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs Gut, May 1, 2004; 53(suppl_4): iv1 - iv24. [Abstract] [Full Text] [PDF]

				D. T. McManus, A. Olaru, and S. J. Meltzer Biomarkers of Esophageal Adenocarcinoma and Barrett's Esophagus Cancer Res., March 1, 2004; 64(5): 1561 - 1569. [Abstract] [Full Text] [PDF]

				E. T. Chang, T. Zheng, E. G. Weir, M. Borowitz, R. B. Mann, D. Spiegelman, and N. E. Mueller Aspirin and the Risk of Hodgkin's Lymphoma in a Population-Based Case-Control Study J Natl Cancer Inst, February 18, 2004; 96(4): 305 - 315. [Abstract] [Full Text] [PDF]

				M. D. Gammon, M. B. Terry, N. Arber, W.-H. Chow, H. A. Risch, T. L. Vaughan, J. B. Schoenberg, S. T. Mayne, J. L. Stanford, R. Dubrow, et al. Nonsteroidal Anti-inflammatory Drug Use Associated with Reduced Incidence of Adenocarcinomas of the Esophagus and Gastric Cardia that Overexpress Cyclin D1: A Population-Based Study Cancer Epidemiol. Biomarkers Prev., January 1, 2004; 13(1): 34 - 39. [Abstract] [Full Text] [PDF]

				W. H. Wang, J. Q. Huang, G. F. Zheng, S. K. Lam, J. Karlberg, and B. C.-Y. Wong Non-steroidal Anti-inflammatory Drug Use and the Risk of Gastric Cancer: A Systematic Review and Meta-analysis J Natl Cancer Inst, December 3, 2003; 95(23): 1784 - 1791. [Abstract] [Full Text] [PDF]

				C J Buskens, A Sivula, B P van Rees, C Haglund, G J A Offerhaus, J J B van Lanschot, and A Ristimaki Comparison of cyclooxygenase 2 expression in adenocarcinomas of the gastric cardia and distal oesophagus Gut, December 1, 2003; 52(12): 1678 - 1683. [Abstract] [Full Text] [PDF]

				L. S. Engel, W.-H. Chow, T. L. Vaughan, M. D. Gammon, H. A. Risch, J. L. Stanford, J. B. Schoenberg, S. T. Mayne, R. Dubrow, H. Rotterdam, et al. Population Attributable Risks of Esophageal and Gastric Cancers J Natl Cancer Inst, September 17, 2003; 95(18): 1404 - 1413. [Abstract] [Full Text] [PDF]

				E. A. Holly and P. M. Bracci Population-based Study of Non-Hodgkin Lymphoma, Histology, and Medical History among Human Immunodeficiency Virus-negative Participants in San Francisco Am. J. Epidemiol., August 15, 2003; 158(4): 316 - 327. [Abstract] [Full Text] [PDF]

				R. E. Rudolph, T. L. Vaughan, A. R. Kristal, P. L. Blount, D. S. Levine, P. C. Galipeau, L. J. Prevo, C. A. Sanchez, P. S. Rabinovitch, and B. J. Reid Serum Selenium Levels in Relation to Markers of Neoplastic Progression Among Persons With Barrett's Esophagus J Natl Cancer Inst, May 21, 2003; 95(10): 750 - 757. [Abstract] [Full Text] [PDF]

				C. J. Henry, D. L. McCaw, S. E. Turnquist, J. W. Tyler, L. Bravo, S. Sheafor, R. C. Straw, W. S. Dernell, B. R. Madewell, L. Jorgensen, et al. Clinical Evaluation of Mitoxantrone and Piroxicam in a Canine Model of Human Invasive Urinary Bladder Carcinoma Clin. Cancer Res., February 1, 2003; 9(2): 906 - 911. [Abstract] [Full Text] [PDF]

				X. Chen, N. Li, S. Wang, J. Hong, M. Fang, J. Yousselfson, P. Yang, R. A. Newman, R. A. Lubet, and C. S. Yang Aberrant arachidonic acid metabolism in esophageal adenocarcinogenesis, and the effects of sulindac, nordihydroguaiaretic acid, and {alpha}-difluoromethylornithine on tumorigenesis in a rat surgical model Carcinogenesis, December 1, 2002; 23(12): 2095 - 2102. [Abstract] [Full Text] [PDF]

				L. R. Kisley, B. S. Barrett, L. D. Dwyer-Nield, A. K. Bauer, D. C. Thompson, and A. M. Malkinson Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice Carcinogenesis, October 1, 2002; 23(10): 1653 - 1660. [Abstract] [Full Text] [PDF]

				T. L. Vaughan, A. R. Kristal, P. L. Blount, D. S. Levine, P. C. Galipeau, L. J. Prevo, C. A. Sanchez, P. S. Rabinovitch, and B. J. Reid Nonsteroidal Anti-inflammatory Drug Use, Body Mass Index, and Anthropometry in Relation to Genetic and Flow Cytometric Abnormalities in Barrett's Esophagus Cancer Epidemiol. Biomarkers Prev., August 1, 2002; 11(8): 745 - 752. [Abstract] [Full Text] [PDF]

				P. S. Carlton, R. Gopalakrishnan, A. Gupta, B. W. Liston, S. Habib, M. A. Morse, and G. D. Stoner Piroxicam Is an Ineffective Inhibitor of N-Nitrosomethylbenzylamine-induced Tumorigenesis in the Rat Esophagus Cancer Res., August 1, 2002; 62(15): 4376 - 4382. [Abstract] [Full Text] [PDF]

				S. T. Mayne, H. A. Risch, R. Dubrow, W.-H. Chow, M. D. Gammon, T. L. Vaughan, D. C. Farrow, J. B. Schoenberg, J. L. Stanford, H. Ahsan, et al. Nutrient Intake and Risk of Subtypes of Esophageal and Gastric Cancer Cancer Epidemiol. Biomarkers Prev., October 1, 2001; 10(10): 1055 - 1062. [Abstract] [Full Text] [PDF]

				L. B. Signorello, W. Ye, J. P. Fryzek, L. Lipworth, J. F. Fraumeni Jr., W. J. Blot, J. K. McLaughlin, and O. Nyren Nationwide Study of Cancer Risk Among Hip Replacement Patients in Sweden J Natl Cancer Inst, September 19, 2001; 93(18): 1405 - 1410. [Abstract] [Full Text] [PDF]

				K. B. Moysich, C. Mettlin, M. S. Piver, N. Natarajan, R. J. Menezes, and H. Swede Regular Use of Analgesic Drugs and Ovarian Cancer Risk Cancer Epidemiol. Biomarkers Prev., August 1, 2001; 10(8): 903 - 906. [Abstract] [Full Text] [PDF]

				K. Saukkonen, O. Nieminen, B. van Rees, S. Vilkki, M. Harkonen, M. Juhola, J.-P. Mecklin, P. Sipponen, and A. Ristimaki Expression of Cyclooxygenase-2 in Dysplasia of the Stomach and in Intestinal-type Gastric Adenocarcinoma Clin. Cancer Res., July 1, 2001; 7(7): 1923 - 1931. [Abstract] [Full Text] [PDF]

				K. Akre, L. B. Signorello, L. Engstrand, R. Bergström, S. Larsson, B. I. Eriksson, and O. Nyrén Risk for Gastric Cancer after Antibiotic Prophylaxis in Patients Undergoing Hip Replacement Cancer Res., November 1, 2000; 60(22): 6376 - 6380. [Abstract] [Full Text]

				B J R WHITTLE COX-1 and COX-2 products in the gut: therapeutic impact of COX-2 inhibitors Gut, September 1, 2000; 47(3): 320 - 325. [Full Text] [PDF]

				G. M. Eisen The Burning Issue of Chronic Gastroesophageal Reflux Ann Intern Med, August 1, 2000; 133(3): 227 - 229. [Full Text] [PDF]

				M J S Langman, K K Cheng, E A Gilman, and R J Lancashire Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database BMJ, June 17, 2000; 320(7250): 1642 - 1646. [Abstract] [Full Text]

				M. Li, R. Lotan, B. Levin, E. Tahara, S. M. Lippman, and X.-C. Xu Aspirin Induction of Apoptosis in Esophageal Cancer: A Potential for Chemoprevention Cancer Epidemiol. Biomarkers Prev., June 1, 2000; 9(6): 545 - 549. [Abstract] [Full Text]

				P. F. Coogan, L. Rosenberg, J. R. Palmer, B. L. Strom, A. G. Zauber, P. D. Stolley, and S. Shapiro Nonsteroidal Anti-Inflammatory Drugs and Risk of Digestive Cancers at Sites Other Than the Large Bowel Cancer Epidemiol. Biomarkers Prev., January 1, 2000; 9(1): 119 - 123. [Abstract] [Full Text]

				H. Vainio and G. Morgan Cyclo-oxygenase 2 and breast cancer prevention BMJ, September 26, 1998; 317(7162): 828 - 830. [Full Text]

				R. A. Gupta, D. B. Polk, U. Krishna, D. A. Israel, F. Yan, R. N. DuBois, and R. M. Peek Jr. Activation of Peroxisome Proliferator-activated Receptor gamma Suppresses Nuclear Factor kappa B-mediated Apoptosis Induced by Helicobacter pylori in Gastric Epithelial Cells J. Biol. Chem., August 10, 2001; 276(33): 31059 - 31066. [Abstract] [Full Text] [PDF]